Article
Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
Circulation. Arrhythmia and electrophysiology - 1 Oct 2016
Chorin Ehud, Hu Dan, Antzelevitch Charles, Hochstadt Aviram, Belardinelli Luiz, Zeltser David, Barajas-Martinez Hector, Rozovski Uri, Rosso Raphael, Adler Arnon, Benhorin Jesaia, Viskin Sami
Abstract excerpt
BACKGROUND: The basic defect in long-QT syndrome type III (LQT3) is an excessive inflow of sodium current during phase 3 of the action potential caused by mutations in the SCN5A gene. Most sodium channel blockers reduce the early (peak) and late components of the sodium current (INa and INaL), but ranolazine preferentially reduces INaL. We, therefore, evaluated the effects of ranolazine in LQT3 caused by the...
Topics
- Adolescent
- Adult
- Aged
- Electrocardiography
- Female
- Humans
- Israel
- Long QT Syndrome
- Male
- Middle Aged
- NAV1.5 Voltage-Gated Sodium Channel
- Phenotype
- Ranolazine
- Sodium Channel Blockers